Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 8 · below the Ichimoku cloud · RSI 30 (oversold) · MACD above its signal · 2% above its 52-week low
None of the 29 investors followed here reported a position in DWTX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a DWTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Nov 20, 2025 | Sealbond LtdBeneficial Owner of more than 10% of a Class of Security | — | 24.45M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -32.9 | 2.2 | -26.0 | -32.2 | 18.2 | -4.7 | 1.9 | 57.3 | -47.7 | -3.7 | −68.7% | ||
| 2025 | 401.6 | -61.6 | 4.6 | 9.4 | -5.5 | -7.9 | 1.4 | 2.6 | 55.2 | -19.4 | 5.0 | -36.2 | +67.1% |
| 2024 | -28.7 | -9.5 | 29.1 | -5.6 | -52.4 | 0.0 | -1.9 | -8.1 | -12.4 | 2.4 | -44.8 | 3.7 | −82.7% |
| 2023 | 30.9 | -2.9 | 22.7 | 98.4 | 135.6 | -19.8 | 37.7 | -42.1 | -15.9 | -40.5 | 3.5 | 1.1 | +143.6% |
| 2022 | 25.1 | -11.6 | -20.8 | -10.5 | 7.0 | -1.4 | 65.5 | 0.9 | -94.6 | -27.8 | 5.5 | -18.6 | −95.4% |
| 2021 | -9.6 | -8.8 | -7.4 | -5.6 | -3.0 | 19.8 | -5.4 | -15.0 | 4.5 | -11.7 | 16.7 | -6.1 | −31.9% |
| 2020 | — |
Buy / hold / sell counts
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.